Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence
Year: 2005
Type: article
Study design: Clinical Trial
Source: Cancer
DOI: 10.1002/cncr.21326
Authors: Richard A. Larson, Eric L. Sievers, Edward A. Stadtmauer, Bob Löwenberg, Elihu H. Estey, Hervé Dombret, Matthias Theobald, Dimitris Voliotis, John M. Bennett, Maria Richie, Lance H. Leopold, Mark S. Berger, Matthew L. Sherman, Michael R. Loken, Jacques J. M. van Dongen, Irwin D. Bernstein, Frederick R. Appelbaum, Mylotarg Study Group
Institutions: University of Chicago, University of Washington, Fred Hutch Cancer Center, University of Pennsylvania, Erasmus MC, The University of Texas MD Anderson Cancer Center, Hôpital Saint-Louis, Johannes Gutenberg University Mainz, University Hospital Cologne, University of Rochester Medicine, Wyeth, University of Rochester
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2065406906